New Biosimilar approval (biologic generic) may save billions in costs for rheumatoid arthritis patients
The biosimilar adventure continues-Somewhat like generic medicines, A new biosimilar for infliximab or (Remicade) got the approval not from the FDA. What this means is that the medicine works to combat rheumatoid arthritis and Chrohn's disease, but costs much much less that the well-known brand.
The Food and Drug Administration.
This site is rich in medicine information, new approvals, recalls, cautions, MedGuides and FDA meetings. You can also report side effects, see reports of side effects and much much more.